Prescription opioids. II. metabolism and excretion patterns of hydrocodone in urine following controlled single-dose administration

Edward J. Cone, Rebecca Heltsley, David L. Black, John M. Mitchell, Charles P. LoDico, Ronald R. Flegel

Research output: Contribution to journalArticle

Abstract

Hydrocodone (HC) is a highly misused prescription drugs in the USA. Interpretation of urine tests for HC is complicated by its metabolism to two metabolites, hydromorphone (HM) and dihydrocodeine (DHC), which are also available commercially and are misused. Currently, there is interest in including HC and HM in the federal workplace drug-testing programs. This study characterized the disposition of HC in human urine. Twelve healthy, drug-free, adults were administered a single, oral 20 mg immediate-release dose of HC in a controlled clinical setting. Urine specimens were collected at timed intervals for up to 52 h and analyzed by LC-MS-MS (limit of quantitation 5 50 ng/mL) with and without enzymatic hydrolysis. All specimens were also analyzed for creatinine and specific gravity (SG). HC and norhydrocodone (NHC) appeared within 2 h followed by HM and DHC. Peak concentrations of HC and metabolites occurred at 3-9 h. Peak hydrolyzed concentrations were in the order: NHC > HC > HM > DHC. Only HM was excreted extensively as a conjugated metabolite. At a cutoff concentration of 50 ng/mL, detection times were ~28 h for HC, 40 h for NHC, 26 h for HM and 16 h for DHC. Some specimens did not contain HC, but most contained NHC, thereby facilitating interpretation that HC was the administered drug. Creatinine and SG measures were highly correlated. Creatinine corrections of HC urinary data had variable effects of lowering or raising concentrations. These data suggest that drug-testing requirements for HC should include a hydrolysis step and a test for HM.

Original languageEnglish (US)
Article numberbkt066
Pages (from-to)486-494
Number of pages9
JournalJournal of Analytical Toxicology
Volume37
Issue number8
DOIs
StatePublished - Oct 2013

Fingerprint

Hydrocodone
Metabolites
Metabolism
excretion
urine
Opioid Analgesics
Prescriptions
drug
Hydromorphone
metabolism
Urine
Density (specific gravity)
metabolite
Enzymatic hydrolysis
Testing
hydrolysis
Hydrolysis
gravity
workplace
Creatinine

ASJC Scopus subject areas

  • Analytical Chemistry
  • Toxicology
  • Health, Toxicology and Mutagenesis
  • Chemical Health and Safety
  • Environmental Chemistry

Cite this

Prescription opioids. II. metabolism and excretion patterns of hydrocodone in urine following controlled single-dose administration. / Cone, Edward J.; Heltsley, Rebecca; Black, David L.; Mitchell, John M.; LoDico, Charles P.; Flegel, Ronald R.

In: Journal of Analytical Toxicology, Vol. 37, No. 8, bkt066, 10.2013, p. 486-494.

Research output: Contribution to journalArticle

Cone, Edward J. ; Heltsley, Rebecca ; Black, David L. ; Mitchell, John M. ; LoDico, Charles P. ; Flegel, Ronald R. / Prescription opioids. II. metabolism and excretion patterns of hydrocodone in urine following controlled single-dose administration. In: Journal of Analytical Toxicology. 2013 ; Vol. 37, No. 8. pp. 486-494.
@article{37ad593c9cc048b78bcef83dc0f8cd3f,
title = "Prescription opioids. II. metabolism and excretion patterns of hydrocodone in urine following controlled single-dose administration",
abstract = "Hydrocodone (HC) is a highly misused prescription drugs in the USA. Interpretation of urine tests for HC is complicated by its metabolism to two metabolites, hydromorphone (HM) and dihydrocodeine (DHC), which are also available commercially and are misused. Currently, there is interest in including HC and HM in the federal workplace drug-testing programs. This study characterized the disposition of HC in human urine. Twelve healthy, drug-free, adults were administered a single, oral 20 mg immediate-release dose of HC in a controlled clinical setting. Urine specimens were collected at timed intervals for up to 52 h and analyzed by LC-MS-MS (limit of quantitation 5 50 ng/mL) with and without enzymatic hydrolysis. All specimens were also analyzed for creatinine and specific gravity (SG). HC and norhydrocodone (NHC) appeared within 2 h followed by HM and DHC. Peak concentrations of HC and metabolites occurred at 3-9 h. Peak hydrolyzed concentrations were in the order: NHC > HC > HM > DHC. Only HM was excreted extensively as a conjugated metabolite. At a cutoff concentration of 50 ng/mL, detection times were ~28 h for HC, 40 h for NHC, 26 h for HM and 16 h for DHC. Some specimens did not contain HC, but most contained NHC, thereby facilitating interpretation that HC was the administered drug. Creatinine and SG measures were highly correlated. Creatinine corrections of HC urinary data had variable effects of lowering or raising concentrations. These data suggest that drug-testing requirements for HC should include a hydrolysis step and a test for HM.",
author = "Cone, {Edward J.} and Rebecca Heltsley and Black, {David L.} and Mitchell, {John M.} and LoDico, {Charles P.} and Flegel, {Ronald R.}",
year = "2013",
month = "10",
doi = "10.1093/jat/bkt066",
language = "English (US)",
volume = "37",
pages = "486--494",
journal = "Journal of Analytical Toxicology",
issn = "0146-4760",
publisher = "Preston Publications",
number = "8",

}

TY - JOUR

T1 - Prescription opioids. II. metabolism and excretion patterns of hydrocodone in urine following controlled single-dose administration

AU - Cone, Edward J.

AU - Heltsley, Rebecca

AU - Black, David L.

AU - Mitchell, John M.

AU - LoDico, Charles P.

AU - Flegel, Ronald R.

PY - 2013/10

Y1 - 2013/10

N2 - Hydrocodone (HC) is a highly misused prescription drugs in the USA. Interpretation of urine tests for HC is complicated by its metabolism to two metabolites, hydromorphone (HM) and dihydrocodeine (DHC), which are also available commercially and are misused. Currently, there is interest in including HC and HM in the federal workplace drug-testing programs. This study characterized the disposition of HC in human urine. Twelve healthy, drug-free, adults were administered a single, oral 20 mg immediate-release dose of HC in a controlled clinical setting. Urine specimens were collected at timed intervals for up to 52 h and analyzed by LC-MS-MS (limit of quantitation 5 50 ng/mL) with and without enzymatic hydrolysis. All specimens were also analyzed for creatinine and specific gravity (SG). HC and norhydrocodone (NHC) appeared within 2 h followed by HM and DHC. Peak concentrations of HC and metabolites occurred at 3-9 h. Peak hydrolyzed concentrations were in the order: NHC > HC > HM > DHC. Only HM was excreted extensively as a conjugated metabolite. At a cutoff concentration of 50 ng/mL, detection times were ~28 h for HC, 40 h for NHC, 26 h for HM and 16 h for DHC. Some specimens did not contain HC, but most contained NHC, thereby facilitating interpretation that HC was the administered drug. Creatinine and SG measures were highly correlated. Creatinine corrections of HC urinary data had variable effects of lowering or raising concentrations. These data suggest that drug-testing requirements for HC should include a hydrolysis step and a test for HM.

AB - Hydrocodone (HC) is a highly misused prescription drugs in the USA. Interpretation of urine tests for HC is complicated by its metabolism to two metabolites, hydromorphone (HM) and dihydrocodeine (DHC), which are also available commercially and are misused. Currently, there is interest in including HC and HM in the federal workplace drug-testing programs. This study characterized the disposition of HC in human urine. Twelve healthy, drug-free, adults were administered a single, oral 20 mg immediate-release dose of HC in a controlled clinical setting. Urine specimens were collected at timed intervals for up to 52 h and analyzed by LC-MS-MS (limit of quantitation 5 50 ng/mL) with and without enzymatic hydrolysis. All specimens were also analyzed for creatinine and specific gravity (SG). HC and norhydrocodone (NHC) appeared within 2 h followed by HM and DHC. Peak concentrations of HC and metabolites occurred at 3-9 h. Peak hydrolyzed concentrations were in the order: NHC > HC > HM > DHC. Only HM was excreted extensively as a conjugated metabolite. At a cutoff concentration of 50 ng/mL, detection times were ~28 h for HC, 40 h for NHC, 26 h for HM and 16 h for DHC. Some specimens did not contain HC, but most contained NHC, thereby facilitating interpretation that HC was the administered drug. Creatinine and SG measures were highly correlated. Creatinine corrections of HC urinary data had variable effects of lowering or raising concentrations. These data suggest that drug-testing requirements for HC should include a hydrolysis step and a test for HM.

UR - http://www.scopus.com/inward/record.url?scp=84888867264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888867264&partnerID=8YFLogxK

U2 - 10.1093/jat/bkt066

DO - 10.1093/jat/bkt066

M3 - Article

VL - 37

SP - 486

EP - 494

JO - Journal of Analytical Toxicology

JF - Journal of Analytical Toxicology

SN - 0146-4760

IS - 8

M1 - bkt066

ER -